Trial · NCT01854918
Adverse events2,525
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,525
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | Year 1: Standard of Care | 43 | 1,227 | |
| other | Bronchitis | Infections and infestations | Year 1: Evolocumab + Standard of Care | 78 | 2,454 | |
| other | Bronchitis | Infections and infestations | Years 2-3: SOC / Evolocumab + SOC | 70 | 1,197 | |
| other | Bronchitis | Infections and infestations | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | 132 | 2,391 | |
| other | Bronchitis | Infections and infestations | Years 2-3: Total | 202 | 3,588 | |
| other | Influenza | Infections and infestations | Year 1: Standard of Care | 28 | 1,227 | |
| other | Influenza | Infections and infestations | Year 1: Evolocumab + Standard of Care | 66 | 2,454 | |
| other | Influenza | Infections and infestations | Years 2-3: SOC / Evolocumab + SOC | 60 | 1,197 | |
| other | Influenza | Infections and infestations | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | 115 | 2,391 | |
| other | Influenza | Infections and infestations | Years 2-3: Total | 175 | 3,588 | |
| other | Nasopharyngitis | Infections and infestations | Year 1: Standard of Care | 108 | 1,227 | |
| other | Nasopharyngitis | Infections and infestations | Year 1: Evolocumab + Standard of Care | 201 | 2,454 | |
| other | Nasopharyngitis | Infections and infestations | Years 2-3: SOC / Evolocumab + SOC | 151 | 1,197 | |
| other | Nasopharyngitis | Infections and infestations | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | 253 | 2,391 | |
| other | Nasopharyngitis | Infections and infestations | Years 2-3: Total | 404 | 3,588 | |
| other | Upper respiratory tract infection | Infections and infestations | Year 1: Standard of Care | 55 | 1,227 | |
| other | Upper respiratory tract infection | Infections and infestations | Year 1: Evolocumab + Standard of Care | 104 | 2,454 | |
| other | Upper respiratory tract infection | Infections and infestations | Years 2-3: SOC / Evolocumab + SOC | 99 | 1,197 | |
| other | Upper respiratory tract infection | Infections and infestations | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | 178 | 2,391 | |
| other | Upper respiratory tract infection | Infections and infestations | Years 2-3: Total | 277 | 3,588 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01854918/events